At the 7th China International Import Expo (CIIE), the Cancer Foundation of China and Asieris Pharmaceuticals signed a strategic cooperation agreement on cervical cancer prevention and control. With a shared goal of accelerating cervical cancer elimination, the two organizations will collaborate to drive a full-spectrum control strategy, advance early diagnosis and treatment of precancerous lesions, and foster long-term standardized management.
In recent years, the Chinese government has placed a strong emphasis on cervical cancer prevention and control. Both the Outline for Healthy China 2030 Initiative and the Outline for Women’s Development in China (2021-2030) highlight cervical cancer prevention and treatment as a key priority in advancing women’s health. In 2023, the National Health Commission, along with nine other ministries, launched the Action Plan for Accelerating the Elimination of Cervical Cancer (2023-2030). In response to these efforts, the Cancer Foundation of China and Asieris Pharmaceuticals have joined forces to further drive cervical cancer prevention and control efforts.
This collaboration will harness the combined strengths of the Cancer Foundation of China and Asieris Pharmaceuticals to create a robust, full-spectrum system for cervical cancer prevention and control. The two organizations will leverage a collaborative group to assess the current landscape of early diagnosis and treatment, share best practices, and identify areas for improvement. They will host academic conferences and training sessions for healthcare professionals, while enhancing medical institutions’ capabilities in early diagnosis, treatment of precancerous lesions, and long-term management. Moreover, the partnership will roll out pilot programs for the use of comprehensive solutions and new technologies in select regions and medical institutions, while developing and bolstering the collaborative models and mechanisms that drive the holistic cervical cancer prevention and control system.
Zhang Yong, chairman of the Cancer Foundation of China, said, “Cervical cancer is a major threat to women’s health, and its prevention and control is a long-term, demanding task. This year marks the 40th anniversary of the Cancer Foundation of China, and for decades, we’ve been dedicated to advancing cervical cancer control. Our partnership with Asieris Pharmaceuticals will take this work to the next level, helping to build a full-spectrum system for this initiative. I’m confident this collaboration will make a meaningful impact on cervical cancer prevention and contribute to the growth of public health in China.”
Kevin Pan, Founder, Chairman and CEO of Asieris Pharmaceuticals, said, “Asieris Pharmaceuticals has long been committed to addressing women’s health needs. Our non-invasive treatment for precancerous cervical lesions, APL-1702, offers not only clinical benefits for early diagnosis and treatment but also supports a fertility-friendly society. It holds great promise as an effective solution for cervical cancer prevention and control. We are thrilled to partner with the Cancer Foundation of China to push forward cervical cancer prevention, accelerate its elimination, and contribute to the Healthy China initiative.”
